This is a pretty good entry point. It could trade down a bit but not much after that report; I would hold back some cash just in case in goes lower. ABT's P/E and PEG are pretty low for a big pharma, and IMO the revenue prospects of its portfolio and its pipeline are very attractive. ABT was one of the first pharmas to go into biologics in a big way and it still enjoys a significant advantage in that area. I have cycled in and out of ABT very successfully the last couple of years, selling ex dividend and then looking for a good reentry point. There really isn't much to dislike here, but do you own research.
I agree with your analysis on the entry point as being fair at these levels but it is possible to be lower on Feb. 3 since it goes ez-dividend on the 2nd. Some folks may be holding to get the dividend and then dump it. Thoughts?
Frankly, considering the fact that ABT's guidance on the low end is a bit n=more bearish than "Street" consensus, the stock is holding up remarkably well. This could be one of those extraordinary instances where the stock is simply washed out.
ABT has always, and will always, trade in a reliable price wave: buy in the mid/high 40s...sell in the low 50s. Once the dividend is declared in mid-February, I suspect the stock will begin to rise on the bullish news, as post-declaration, ABT will likely be yielding 4% ( assuming a flat share price until said declaration date ).
While guidance is on the low end, you whould keep in mind that at a P/E of just 12 on that guidance, we should be in the mid 50s. In the near term, we could go down on technicals, but this stock is still at a very attractive price.